In Case You Missed It Monday: Markets Punch Through Record Highs
Monday marked the 40-year anniversary of the feature film "Rocky" which grossed more than $250 million worldwide in box office sales.

If you'd like to receive "In Case You Missed It" in your email inbox every evening, please register for TheStreet Alerts and follow me.

Investors came out swinging Monday, the 40th anniversary of the "Rocky" movie franchise's debut, as the Trump rally resumed and indices finished higher across the board. No coincidence, the U.S. dollar continued to strengthen while oil prices also rose on OPEC and Russian production freeze possibilities.  

But the record-setting market moves of the day weren't the only thing TheStreet and its affiliates were eyeing on a Monday, that, like so many others, started with a tech merger bang.

Security software maker Symantec   (SYMC)   agreed to buy LifeLock  (LOCK) for $2.3 billion, while MACOM Technology Solutions Holdings  (MTSI)  announced that it had agreed to purchase fellow semiconductor provider Applied Micro Circuits  (AMCC) for $770 million, continuing a wave of chip consolidation.

So while the markets (FANG's Facebook (FB) , Amazon (AMZN) , Netflix (NFLX) and Alphabet (GOOGL) helped the rally) spiked and dealmakers worked to get last-minute transactions in before the holiday weekend TheStreet and its affiliates were busy helping you prepare for holiday shopping, manage your investments through this unprecedented rally and, all-in-all, help make you some money.

Here are the highlights:

Instagram Is Facebook's Biggest Weapon in Its Battle Against Snapchat
As Snapchat's parent gets ready to go public, Facebook (FB) is pulling out all the stops to slow down its rival. Instagram, which just added live video support, looms large. Full story

Buy Target, Wal-Mart and UPS for a Happy Holiday
Here's a good way to play the looming shopping season. (UPS) , (WMT) , (UPS)  Full story

Tweet of the Day:

Will Tesla's Solar Roof Really Cost Less Than Normal Roof as Musk Claims? Probably not https://t.co/cU1XOFfcKU via @TheStreet $TSLA #tesla

— Tom Terrarosa (@TomTerrarosa) November 21, 2016

Acorda Stroke Study Fails, Dampening Revenue Growth Plans
A mid-stage study of Ampyra in patients with walking difficulties following a stroke "did not show sufficient efficacy" to support further clinical development, Acorda (ACOR) said Monday. Full story

Don't Trade Into OPEC Meeting, Jack Mohr Says
Ahead of the Nov. 30 OPEC meeting, TheStreet's Chief Investment Strategist thinks volatile oil prices will continue. Full story

Chart of the Day: Foot Locker Has the Inside Lane on New Highs

(FL) could see longer-term gains to the low $90s if the stock can break out above $75. Full story

Anthem Lays Out Where It Plans to Attack DOJ Case
The trial begins over the fate of Anthem's (ANTM) $55 billion combination with Cigna (CI) . Full story

Video of the Day: BlackRock's Best Places to Find Yield in 2017

Interest rates remain low despite the surge in yield since the election. Here are the best asset classes to find yield heading into 2017.

If you liked this article you might like

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Stiff-Arms Investor's Demand for Sale

Acorda Stiff-Arms Investor's Demand for Sale